GlassScriptPhysician profile
Khaleel K Ashraf
NPI 1760437925
$379,179.44
in general payments reported to CMS, 2019-2025
89 companies · $6,196 in 2025
The $6,196 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82K · 2020: $89K · 2021: $49K · 2022: $75K · 2023: $44K · 2024: $34K · 2025: $6,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Consulting Fee: $23K · Food and Beverage: $15K · Travel and Lodging: $6,572 · Honoraria: $1,750 · Long Term Medical Supply Or Device Loan: $167 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,091.50 |
| Consulting Fee | $23,396.00 |
| Food and Beverage | $15,225.70 |
| Travel and Lodging | $6,572.33 |
| Honoraria | $1,750.00 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $133.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $60,086.77 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Amgen INC. | $59,552.29 | 2019-2024 | Kyprolis, Blincyto |
| Celgene Corporation | $37,155.17 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals LP | $29,464.86 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| Takeda Pharmaceuticals U.S.A., INC. | $24,604.67 | 2019-2025 | Ninlaro, Fruzaqla, Iclusig |
| Karyopharm Therapeutics INC. | $19,774.02 | 2020-2025 | Xpovio |
| Alexion Pharmaceuticals, INC. | $19,561.94 | 2019-2025 | Ultomiris, Soliris |
| Glaxosmithkline, LLC. | $19,230.64 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| E.R. Squibb & Sons, L.L.C. | $16,454.97 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Pfizer INC. | $14,305.43 | 2019-2025 | |
| Sobi, INC | $9,929.84 | 2022-2025 | |
| Abbvie INC. | $9,181.49 | 2019-2025 | Venclexta, Creon |
| Exelixis INC. | $6,561.46 | 2019-2024 | Cabometyx |
| Genzyme Corporation | $6,485.29 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $6,274.18 | 2019-2025 |
Show all 87 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $5,369.01 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Acrotech Biopharma INC. | $5,342.15 | 2021-2024 | Beleodaq |
| Global Blood Therapeutics, INC. | $3,469.42 | 2020-2022 | |
| Puma Biotechnology, INC. | $3,240.05 | 2019-2024 | |
| Dova Pharmaceuticals | $2,335.86 | 2020-2021 | |
| Kite Pharma, INC. | $1,985.41 | 2019-2025 | Yescarta |
| Cti Biopharma Corp. | $1,852.05 | 2022-2023 | Vonjo |
| G1 Therapeutics, INC. | $1,500.00 | 2021 | |
| Eisai INC. | $1,487.92 | 2019-2025 | |
| Janssen Biotech, INC. | $1,429.43 | 2019-2025 | Darzalex, Rybrevant, Tecvayli |
| Mckesson Specialty Care Distribution, LLC | $1,410.07 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $1,223.61 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| US Oncology Corporate, INC. | $946.89 | 2022-2025 | |
| Lilly USA, LLC | $709.38 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $542.97 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Beigene, LTD. | $525.00 | 2021 | |
| Seagen INC. | $504.54 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $391.21 | 2019-2025 | |
| Daiichi Sankyo INC. | $387.30 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Csl Behring | $368.60 | 2019-2025 | Hizentra |
| Blueprint Medicines Corporation | $356.39 | 2020-2025 | Ayvakit |
| Pharmacyclics LLC, An Abbvie Company | $352.21 | 2019-2023 | Imbruvica |
| Beigene USA, INC. | $347.18 | 2020-2025 | Brukinsa, Tevimbra |
| Deciphera Pharmaceuticals INC. | $337.01 | 2022-2025 | Qinlock, Romvimza, Tgct |
| Regeneron Healthcare Solutions, INC. | $249.44 | 2019-2025 | Libtayo |
| Intera Oncology, INC | $223.00 | 2023 | Intera 3000 Implantable Pump |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.85 | 2019-2025 | Gilotrif |
| Gilead Sciences, INC. | $207.84 | 2019-2025 | Trodelvy |
| Myriad Genetic Laboratories, INC. | $200.62 | 2021-2023 | Precisetumor |
| Jazz Pharmaceuticals INC. | $196.04 | 2020-2025 | Zepzelca |
| Astellas Pharma US INC | $176.06 | 2021-2025 | Padcev, Xtandi, Xospata |
| Pharmaessentia USA Corporation | $159.88 | 2023-2025 | Besremi |
| Beone Medicines USA, INC. | $140.96 | 2025 | Brukinsa, Tevimbra |
| Servier Pharmaceuticals LLC | $139.38 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $124.45 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $122.84 | 2021-2024 | Onivyde, Somatuline Depot |
| Onmark, INC. | $121.63 | 2023 | |
| Array Biopharma INC | $116.25 | 2021-2025 | Braftovi, Lorbrena |
| Stemline Therapeutics INC. | $113.81 | 2023-2025 | Orserdu |
| Coherus Oncology, INC. | $96.89 | 2023-2025 | Loqtorzi |
| Lexicon Pharmaceuticals, INC. | $92.51 | 2019-2020 | |
| Kyowa Kirin, INC. | $90.81 | 2019-2025 | |
| Taiho Oncology, INC. | $90.63 | 2021-2025 | |
| Pharmacosmos Therapeutics INC. | $79.01 | 2020-2025 | Monoferric |
| Agios Pharmaceuticals, INC. | $76.29 | 2023-2025 | Pyrukynd |
| Tempus Ai, INC | $75.61 | 2024 | |
| Emd Serono, INC. | $74.12 | 2021-2024 | Bavencio |
| Mirati Therapeutics, INC. | $72.28 | 2023 | Krazati |
| Adaptive Biotechnologies Corporation | $71.51 | 2023-2024 | Clonoseq |
| Tesaro, INC. | $68.55 | 2019 | |
| Sanofi-Aventis U.S. LLC | $58.51 | 2021 | |
| Recordati_rare_diseases_inc. | $52.47 | 2025 | Sylvant |
| Tersera Therapeutics LLC | $51.15 | 2022-2025 | Quzyttir |
| Aveo Pharmaceuticals, INC. | $50.87 | 2022-2025 | |
| Shield Therapeutics INC | $50.47 | 2023-2024 | Accrufer |
| Adc Therapeutics America, INC. | $50.28 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $45.16 | 2022-2025 | Givlaari |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.36 | 2025 | Relistor |
| Sumitomo Pharma America, INC. | $41.01 | 2024-2025 | Orgovyx |
| Apellis Pharmaceuticals, INC. | $37.87 | 2024 | Empaveli |
| Genmab U.S., INC. | $34.92 | 2024 | Epkinly |
| Epizyme, INC. | $34.65 | 2021-2022 | |
| Morphosys, US INC. | $33.60 | 2022-2023 | Monjuvi |
| Eusa Pharma (US) LLC | $26.82 | 2021 | |
| Azurity Pharmaceuticals, INC. | $23.73 | 2025 | Danziten |
| Accord Healthcare, INC. | $21.06 | 2023 | |
| Spectrum Pharmaceuticals INC. | $18.23 | 2025 | Rolvedon |
| Novocure INC. | $16.28 | 2025 | Optune Lua (Novottf-200t) |
| Progenics Pharmaceuticals, INC. | $15.00 | 2023 | Pylarify |
| Sandoz INC. | $14.58 | 2020 | |
| Mylan Institutional INC. | $13.48 | 2022 | |
| Clovis Oncology, INC. | $11.00 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaleel Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.